Next, in order to better understand which, if any, driver mutations besides NF2 may be associated with cancer initiation, progression, and metastases, we used Cancer Genome Interpreter (CGI) to assign known or predicted novel driver status to nonsynonymous mutations. This evidence concerns the gene NF2 and cancer.